陈列平:开启“免疫正常化”肿瘤免疫治疗新纪元

A new era of immune normalization cancer immunotherapy initiated by CHEN Lieping

癌症免疫治疗,利用抗体阻断介导肿瘤免疫逃逸的通路,尤其是PD-1/B7-H1(PD-L1)通路,可以激活肿瘤免疫反应来控制肿瘤生长,在多种肿瘤治疗中取得了突破性的疗效,从而荣获2018年诺贝尔生理学或医学奖。陈列平最早于1999年克隆B7-H1,并阐明其在癌症免疫中的关键作用,是这一通路应用于癌症治疗的重要奠基人和推动者。文章沿着癌症免疫治疗领域发展的时间轴,回顾陈列平在该领域的重要贡献,揭示PD通路成功应用于癌症免疫治疗的原因和特点,并展望该领域未来的发展方向。

Cancer immunotherapy by antibody blockade of immune evasion mechanisms, especially the PD-1/B7-H1(PD-L1) pathway, elicits strong antitumor immunity and shows prolonged and ground-breaking therapeutic effect in various types of human cancers, which is awarded Nobel prize in Physiology or Medicine in 2018. Dr. Chen Lieping who first cloned B7-H1 in 1999 and clarified its critical function in cancer immunity,laid the foundation for this field and the success application of PD pathway in the treatment of cancer. This article reviews the major contributions of Dr. Chen along the timeline of the progress of cancer immunotherapy, highlighting the distinct features of PD pathway and discussing the prospects of the field.